Antiparkinsonian Agents, Anticholinergic Agents Flashcards
(54 cards)
Increases the risk of psychosis
Effective in the urgent treatment of Neuroleptic malignant syndrome (NMS)
bromocriptine (Parlodel)
Used for: Dystonia, Parkinsonism, Akinesia, Akathisia
benztropine (Cogentin)
Cogentin
1-2 mg BID
PO/IM/IV
benztropine
__________ is responsible for:
S - salivation
L – lacrimation (tearing of the eyes)
U - urination
D - diarrhea
G – gastrointestinal motility
E - emesis
Acetylcholine
is a chronic progressive, degenerative disorder of the CNS
Symptoms:
resting tremor
bradykinesia
rigidity
postural instability
Risk Factors:
Age
Genetics
Sex
Exposure to Toxins
Parkinsons disease
Part of the Extrapyramidal Nervous System
Controls motor movement
Nigrostriatal pathway
Dopamine in Nigrostriatal pathway:
Decrease in Dopamine
Results in: __________
Parkinson Disease and EPS
Dopamine in Nigrostriatal pathway:
Chronic Blockage of D2 Receptors
Results in: __________
Hyperkinetic Movement Disorder (Tardive Dyskinesia)
______ of d2 receptors or ____ dopamine levels – difficulty controlling voluntary and involuntary muscle movement
Loss; low
___________ nervous system nerve fibres that are responsible brainstem to motor fibres of spinal cord (unconscious, reflexive or responsive control of musculature – muscle tone, balance, posture, locomotion)
Extrapyramidal
There is a reciprocal relationship between __________ and _________
Dopamine; Acetylcholine
Normal Functioning = Dopamine controls ____________ release
acetylcholine
widening the blood vessels in the cardiovascular system allowing blood to flow more easily.
Vasodilator
Blocking Dopamine (=decrease d2) causes an increase in ______
Increasing d2=decrease in Ach
ACh
_____ – receptor sites found in NIGROSTRIATAL pathways, dicephalon, medulla
Also found in peripheral nervous system – (rest and digest – parasympathetic)
CNS
________ receptor sites – found in parasympathetic nervous system
Cholinergic
Increase in acetylcholine activity = increase in ___________ side effects (nigrostriatal pathway)
extrapyramidal
_________ acetylcholine activity by reducing Dopamine increases the risk of EPS
Increasing
_____ potency antipsychotics have a high risk of EPS because of potency of dopamine blocking – hence increase in acetylcholine release – lower risk of anticholinergic effects
High
______ potency antipsychotics have a lower risk of EPS because potency of dopamine blocking is not as high and therefore not as much acetylcholine is released - but a much higher risk of _________ effects
Low; anticholinergic
Increase dopamine activity in the brain
E.g. bromocriptine (Parlodel)
Dopamine Receptor Agonists
Prevent the breakdown of brain dopamine by inhibiting the brain enzyme monoamine oxidase B
MAO-B Inhibitors
Inhibit the action of acetylcholine in the brain and affect the parasympathetic nervous system.
E.g. benztropine (Cogentin)
Anticholinergic Drugs
Both compete or inhibit histamine from binding at receptors
Anticholinergic antagonist (works on those receptors as well)
Antihistaminergic